| Drug General Information |
| Drug ID |
D01XEQ
|
| Former ID |
DCL000945
|
| Drug Name |
R348
|
| Indication |
Psoriasis [ICD9: 696; ICD10:L40]
|
Terminated |
[1]
|
|---|
| Company |
Rigel Pharmaceuticals
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Target and Pathway |
| Target(s) |
Tyrosine-protein kinase JAK3 |
Target Info |
Inhibitor |
[1]
|
|---|
|
KEGG Pathway
|
Chemokine signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
Signaling pathways regulating pluripotency of stem cells
|
|
Jak-STAT signaling pathway
|
|
Measles
|
|
HTLV-I infection
|
|
Epstein-Barr virus infection
|
|
Viral carcinogenesis
|
|
Primary immunodeficiency
|
|
PANTHER Pathway
|
Interleukin signaling pathway
|
|
JAK/STAT signaling pathway
|
|
PDGF signaling pathway
|
|
Pathway Interaction Database
|
IL4-mediated signaling events
|
|
CD40/CD40L signaling
|
|
Signaling events mediated by TCPTP
|
|
SHP2 signaling
|
|
IL2-mediated signaling events
|
|
IL2 signaling events mediated by PI3K
|
|
IL2 signaling events mediated by STAT5
|
|
Reactome
|
GPVI-mediated activation cascade
|
|
Interleukin-7 signaling
|
|
G beta:gamma signalling through PI3Kgamma
|
|
Interleukin-2 signaling
|
|
RAF/MAP kinase cascade
|
|
Interleukin receptor SHC signaling
|
|
WikiPathways
|
IL-2 Signaling Pathway
|
|
IL-4 Signaling Pathway
|
|
Interleukin-2 signaling
|
|
Interleukin-7 signaling
|
|
Oncostatin M Signaling Pathway
|
|
IL-9 Signaling Pathway
|
|
IL-7 Signaling Pathway
|
|
Interleukin-3, 5 and GM-CSF signaling
|
| References |
| REF 1 | Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63. |
|---|
